Last reviewed · How we verify

Indomethacin 0.5% eyedrops — Competitive Intelligence Brief

Indomethacin 0.5% eyedrops (Indomethacin 0.5% eyedrops) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Ophthalmology.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1, COX-2) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Indomethacin 0.5% eyedrops (Indomethacin 0.5% eyedrops) — Università degli Studi di Brescia. Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Indomethacin 0.5% eyedrops TARGET Indomethacin 0.5% eyedrops Università degli Studi di Brescia phase 3 Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1, COX-2)
Prednisone and Aspirin Prednisone and Aspirin Second Affiliated Hospital, School of Medicine, Zhejiang University marketed Corticosteroid and nonsteroidal anti-inflammatory drug (NSAID) combination Glucocorticoid receptor (prednisone); Cyclooxygenase-1 and Cyclooxygenase-2 (aspirin)
Pranoprofen eye drops Pranoprofen eye drops Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1, COX-2)
Aspirin (acetylsalicylic acid) Aspirin (acetylsalicylic acid) Swedish Medical Center marketed Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Ibuprofen Acid Ibuprofen Acid Reckitt Benckiser Healthcare (UK) Limited marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2
aspirin + celecoxib aspirin + celecoxib Seoul National University Hospital marketed Nonsteroidal anti-inflammatory drug (NSAID) combination COX-1 and COX-2 enzymes
ketorolac 0.5% ketorolac 0.5% Queen's University marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

  1. Università degli Studi di Brescia · 4 drugs in this class
  2. Bausch & Lomb Incorporated · 4 drugs in this class
  3. Bayer · 3 drugs in this class
  4. Pfizer · 3 drugs in this class
  5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
  6. Organon and Co · 3 drugs in this class
  7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
  8. Bezmialem Vakif University · 2 drugs in this class
  9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
  10. Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Indomethacin 0.5% eyedrops — Competitive Intelligence Brief. https://druglandscape.com/ci/indomethacin-0-5-eyedrops. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: